About this episode

The episode discusses the impact of multimodal aging signatures and proteomic biomarkers on multiple sclerosis care.

Guest: Adil Harroud, MD Guest: Dylan Hamitouche Host: Ryan Quigley Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS, a topic they presented on at the 2026 ACTRIMS Forum. Dr. Harroud is a neurologist and the co-leader of the Neuroimmunology Diseases Research Group at the Montreal Neurological Institute at McGill University. Mr. Hamitouche is a medical student at McGill University.

More episodes of NeuroFrontiers

• Cognitive Screening in MS: Practical Strategies and Modern Approaches · May 28, 2026 · 4 min
• Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols · May 14, 2026 · 14 min
• Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role · May 14, 2026 · 15 min
• Examining the Global Genetic Prevalence of TK2d · April 30, 2026 · 14 min
• Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis · March 30, 2026 · 3 min
• Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care · February 19, 2026 · 5 min

Explore listener stats, chart rankings, contacts and more on the NeuroFrontiers podcast page.